Vivos Therapeutics (VVOS) Competitors

TELA Bio (NASDAQ:TELA) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, community ranking, earnings, profitability, valuation, dividends and institutional ownership.

Does the MarketBeat Community prefer TELA or VVOS?

TELA Bio received 43 more outperform votes than Vivos Therapeutics when rated by MarketBeat users. Likewise, 73.17% of users gave TELA Bio an outperform vote while only 53.13% of users gave Vivos Therapeutics an outperform vote.

Company	Underperform	Outperform
TELA Bio	Outperform Votes 60 73.17%	Underperform Votes 22 26.83%
Vivos Therapeutics	Outperform Votes 17 53.13%	Underperform Votes 15 46.88%

Which has more risk & volatility, TELA or VVOS?

TELA Bio has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 7.02, indicating that its stock price is 602% more volatile than the S&P 500.

Do insiders and institutionals hold more shares of TELA or VVOS?

94.3% of TELA Bio shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 4.7% of TELA Bio shares are held by company insiders. Comparatively, 3.0% of Vivos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Is TELA or VVOS more profitable?

TELA Bio has a net margin of -60.49% compared to Vivos Therapeutics' net margin of -86.19%. Vivos Therapeutics' return on equity of -335.04% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TELA Bio	-60.49%	-556.18%	-63.13%
Vivos Therapeutics	-86.19%	-335.04%	-93.58%

Which has better valuation and earnings, TELA or VVOS?

Vivos Therapeutics has lower revenue, but higher earnings than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TELA Bio	$71.22M	1.04	-$46.66M	-$1.41	-1.33
Vivos Therapeutics	$14.63M	0.89	-$13.58M	-$1.73	-1.28

Do analysts recommend TELA or VVOS?

TELA Bio currently has a consensus target price of $7.25, suggesting a potential upside of 287.70%. Vivos Therapeutics has a consensus target price of $4.82, suggesting a potential upside of 116.97%. Given TELA Bio's stronger consensus rating and higher possible upside, research analysts plainly believe TELA Bio is more favorable than Vivos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TELA Bio	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Vivos Therapeutics	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Does the media prefer TELA or VVOS?

In the previous week, TELA Bio had 2 more articles in the media than Vivos Therapeutics. MarketBeat recorded 6 mentions for TELA Bio and 4 mentions for Vivos Therapeutics. TELA Bio's average media sentiment score of 0.87 beat Vivos Therapeutics' score of 0.57 indicating that TELA Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TELA Bio	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vivos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

TELA Bio beats Vivos Therapeutics on 14 of the 18 factors compared between the two stocks.